Australia's largest stock trading and investment forum Australia's #1 stock forum

ESS essential metals limited

0.00%

50.0¢

when you say “may need”, is your interpretation that it’s still...

First 91 Last

Share
Profile

Follow
malvernmoe

1,084 Posts.

504

31/01/23

12:49

Post #: 65974802
Share

Originally posted by WhatsTheTip: ↑

@dynofish, although Core's DSO is ore that can be processed to Spod using simple DMS processes for acceptable recovery rates. A lot depends on how the purchasers of the DSO intended to recover the lithium units contained in the material. If it was to process through to Spod and then continue the normal flow sheet from Spod to hydroxide then there may be a distinct price difference between DMS capable DSO and DSO that needed DMS and a flotation circuit to achieve acceptable recoveries.

ESS DSO may need a more complicated processing solution to get acceptable recoveries for the buyer of the DSO (and this issue will also impact on the capital cost appearing in the upcoming scoping study). Needing a flotation circuit to get acceptable recoveries may reduce the range of buyers interested in ESS DSO and may then also reduce the price received for it. What examples exist of DSO sales where the ore requires flotation to get acceptable or semi-acceptable recovery rates are there?

Expand

when you say “may need”, is your interpretation that it’s still no definitive?

ESS Price at posting: 53.5¢ Sentiment: None Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

MVF

Monash IVF shares cater 25% – Disaster or deep-value play?

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

First 91 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

when you say “may need”, is your interpretation that it’s still...

Top Stories

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Monash IVF shares cater 25% – Disaster or deep-value play?

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Featured News